TREATMENT OF TYPE 2 DIABETES, METABOLIC SYNDROME, MYOCARDIAL INJURY AND NEURODEGENERATION WITH HUMANIN AND ANALOGS THEREOF
Provided are methods of using humanin and humanin analogs to treat a mammal exhibiting or at risk for insulin resistance, increase insulin sensitivity in a mammal exhibiting or at risk for insulin resistance, treat type-2 diabetes mellitus, metabolic syndrome, and neurodegeneration, treat and prevent myocardial injury, and determine longevity.
1 - 91 . (canceled)
92 . A pharmaceutical composition for increasing insulin sensitivity comprising humanin or a humanin analog in an amount effective to increase insulin sensitivity and a pharmaceutically acceptable carrier, wherein humanin or the humanin analog comprises the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11 or SEQ ID NO:19.
93 . The pharmaceutical composition of claim 92 , wherein humanin has the amino acid sequence of SEQ ID NO:1.
94 . The pharmaceutical composition of claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:2.
95 . The pharmaceutical composition of claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:3.
96 . The pharmaceutical composition of claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:4.
97 . The pharmaceutical composition of claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:5.
98 . The pharmaceutical composition of claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:6.
99 . The pharmaceutical composition of claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:7.
100 . The pharmaceutical composition of claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:8.
101 . The pharmaceutical composition of claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:9.
102 . The pharmaceutical composition of claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:11.
103 . The pharmaceutical composition of claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:19.
104 . The pharmaceutical composition of claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:10 conjugated to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11 or SEQ ID NO:19.
105 . The pharmaceutical composition of claim 104 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:10 at the N-terminus of the amino acid sequence of amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11 or SEQ ID NO:19.
106 . A method of increasing insulin sensitivity in a subject exhibiting insulin resistance comprising administering the pharmaceutical composition of claim 92 to the subject.
107 . A method of treating type-2 diabetes mellitus in a subject comprising administering the pharmaceutical composition of claim 92 to the subject.